VEGFA and neoplasm: Co-targeting of TAMs and VEGF with the combination PLX3397 and cediranib (AZD2171), a VEGF-inhibitor, revealed decreased angiogenesis and vessel density as well as reduced tumor cell proliferation in RAS-driven mesenchymal GBM [33].